BioAdaptives Details Xcellara Platform Strategy Ahead of XcellaraHeart Launch

BioAdaptives (OTC: BDPT) has detailed the scientific strategy behind its Xcellara cellular wellness platform, setting the stage for the planned Aug. 1 commercial launch of XcellaraHeart. The platform integrates a stem/progenitor cell mobilization base, supported by a human randomized controlled trial showing an average 268.8% increase in circulating stem/progenitor-type cells, with tissue-specific ingredients designed to support the body’s natural signaling pathways and direct those cells to targeted areas.

XcellaraHeart, the platform’s first commercial application, pairs the Xcellara base with Tanshinone IIA, a compound derived from Danshen that has been studied for its role in cardiovascular SDF-1α/CXCR4 signaling. This combination aims to enhance the body's natural repair mechanisms by mobilizing stem cells and guiding them to cardiac tissues. The company plans to expand the platform with additional formulas targeting wellness categories including joint mobility, skin health, cognitive wellness, and metabolic resilience, using the same supply-and-direction development model.

The Xcellara base formula is notable as the only dietary supplement with a human randomized, double-blind, placebo-controlled clinical trial demonstrating a 268.8% increase in circulating hematopoietic stem and progenitor cells at four weeks, with zero adverse effects on more than twenty blood parameters. The product line includes seven targeted formulas that combine the clinically proven mobilization base with tissue-specific signaling ingredients for cardiac, joint, neural, dermal, longevity, and stress-resilience applications.

For more information, the complete scientific evidence dossier for the XcellaraHeart formulation will be available at products.xcellara.com/science. The dossier separates what has been demonstrated in BioAdaptives’ human clinical research on the Xcellara base from published research on Tanshinone IIA and from the company’s product-development rationale for combining the two. Additional details about the company and its products can be found at www.bioadaptives.com.

This announcement is significant as it marks the commercialization of a platform that leverages clinically validated stem cell mobilization technology, potentially offering new approaches to supporting cardiovascular health and other wellness areas. The strategy underscores BioAdaptives' commitment to evidence-based supplementation, with the Xcellara platform representing a novel approach to directing the body's own regenerative cells to specific tissues.